Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07462702

Topical Minocycline for CARP

This proof-of-concept trial evaluates the efficacy, safety, and patient satisfaction of topical minocycline foam (AMZEEQ®) in patients aged 9 and older with confluent and reticulated papillomatosis (CARP). Participants will apply AMZEEQ® to one side of the body and a topical emollient to the other for 5 weeks, followed by an optional extension period. The study aims to assess whether topical minocycline is a well-tolerated and effective alternative to oral antibiotics.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Confluent and Reticulated Papillomatosis (CARP) Papillomatosis, Familial Cutaneous Pathological Conditions, Signs and Symptoms Pruritus Signs and Symptoms Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases cyclopia sequence

Age range

9 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

About this study

Confluent and reticulated papillomatosis (CARP) is a dermatologic condition consisting of primarily truncal hyperpigmented and hyperkeratotic papules and macules in adolescents. The exact cause is unclear, though a gram-positive actinomycete, Dietzia papillomatosis, likely plays a role. Resolution of the rash could take a year or even years to fully occur. While the gold-standard is to treat with oral minocycline (100 mg daily), preliminary data suggests that topical minocycline may be effective as well. A case report of a 51-year-old female documents clearance with topical minocycline foam. Other antibiotics can be considered as well, such as azithromycin and erythromycin. Antifungal medications can also be considered as well as topicals such as tretinoin, tacrolimus, and urea.

Oral minocycline has a number of side effects and cannot be used in pregnancy. Given side effects and risks of lengthy oral antibiotic treatment, investigators believe that utilization of topical minocycline foam could be a suitable option for patients, especially those who do not want to be treated with oral minocycline for an extended period of time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 9 years
  • Clinical diagnosis of CARP

Exclusion criteria

  • Current or recent (within 6 months) use of oral minocycline
  • Pregnancy or breastfeeding
  • History of intracranial hypertension, autoimmune disorder, liver/kidney disease
  • Immunocompromised status
  • Hypersensitivity to tetracyclines
  • Unstable medical condition
  • Inability or unwillingness to provide informed consent

Treatment and study plan

Topical Minocycline Foam FXFM244

Drug

Topical minocycline foam that will be applied to half of the subject's body that will be chosen by the subject.

Control

Other

Control topical emollient that will be applied to the contralateral half of the body.

Primary outcomes

  1. Change in analog score based on blinded reviewer analysis of individuals treated with both daily topical AMZEEQ® (minocycline) compared to topical emollient

    Time frame: 5 +/- 1 weeks

    Comparison between the efficacy of topical minocycline foam and the control emollient. This will be completed by a dermatologist or dermatology resident that will be blinded to which side was treated with which intervention. Assessment will be completed through a visual analog used by the assessor where REDCap will assign a numeric value based on the position of the marking. The blinded photo reviewer will be informed whether the photo is a baseline or follow-up photo, but will be blinded to which side of the body was treatment or control. The photos will be marked to indicate the side of the body, and the photo reviewer will be asked to compare the left baseline side to the left follow-up side, and similarly the right baseline to the right follow-up, using a visual sliding analogue scale, where REDCap will assign a numeric value based on the position of the marking indicator. Average response to treatment among all patients will be determined.

Secondary outcomes

  1. Assess possible adverse effects secondary to topical minocycline (AMZEEQ) use

    Time frame: 6 +/- 1 weeks

    Prior to beginning treatment, subjects will fill out a survey including the following conditions: headache, erythema, dry skin, hyperpigmentation, skin peeling, itching, GI upset, bone or muscle pain, photosensitivity, serious skin hypersensitivity reactions, delayed wound healing, nail changes, or infection. After completing the course of topical minocycline foam, patients will complete a follow up form again through REDCap which will be compared to the form completed at baseline.

  2. Discern patient satisfaction with daily topical minocycline (AMZEEQ) use compared to daily topical emollient

    Time frame: 6 +/- 1 weeks

    To determine patient satisfaction, the Children's Dermatology Life Quality Index (CDLQI) survey for ages 4-16 or Dermatology Life Quality Index (DLQI) survey for ages 16+ will be administered at baseline before receiving the study drug and at each 6-week ± 5 day follow-up visit via REDCap. The CDLQI and DLQI surveys are the most frequently used validated, patient-reported outcome measure in dermatology trials. The DLQI is a 10-question, self-administered survey for patients over 16, designed to measure how skin conditions impact daily life over the past week. It covers symptoms, daily activities, leisure, work/school, personal relationships, and treatment, with a total score of 0-30 where higher scores indicate greater impairment. The CDLQI contains many of the same questions as the DLQI, but is administered to patients from the ages of 4 to 16.

Sponsors and collaborators

Lead sponsor

Medical University of South Carolina

Other

Collaborators

  • Journey Medical Corporation

Registry information

Official study title

Topical Minocycline Foam for Treatment of Confluent and Reticulated Papillomatosis (CARP)

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Mar 10, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.